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A variety of reference curves are used to derive predicted values for adult lung function,
even within ethnically similar populations. Alternatives to percentage predicted value are
sometimes used to allow for height in research. Strength of association with total mortality
can be used to choose the optimal expression, between forced expiratory volume in 1 s
(FEV1) divided by height
2, FEV1/height
3, FEV1% predicted and difference from predicted.
Data from the Reykjavik Study cohort, 1976–2002, included 5544 men and 8062 women
randomly selected from the population. Total mortality was analysed by Cox proportional
hazards regression in relation to each height-adjusted measure, allowing for age group,
period of recruitment and body mass index, and smoking before or at baseline.
FEV1/height
2 and FEV1/height
3 had stronger associations with mortality than FEV1%
predicted and difference from predicted in men and in women. There were similar findings
for forced vital capacity (FVC) in non-smokers and in women. FEV1/height
2 was slightly
better predictive than FEV1/height
3 in men, but distributions of FEV1/height
3 in men and
women were closer than those of FEV1/height
2.
Clinical practise and epidemiological research would benefit from agreement on how to
adjust lung function for height. Replication of these analyses in other cohort studies would
inform the choice between FEV1/height
2 and FEV1/height
3.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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k (S. Chinn).Introduction
Measures of lung function, forced expiratory volume in 1 s
(FEV1) and forced vital capacity (FVC) in particular, are
commonly expressed as a percentage of a predicted value
for age, height and sex.1,2 Recent recommendations specify
that predicted values should be taken from a population of
the same age-range, ethnic group and sex.3 Some ethnic
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there is variation even within those derived from white
populations.6 To avoid choice of reference curves, or
selection of inappropriate values, study-specific predicted
values are often used in epidemiological studies.7–14
Predicted values are usually derived from multiple
regression equations of lung function on height and age,
for men and women separately.4–6 In analyses of lung
function, a number of methods of adjustment for height
are found, in addition to use of % predicted. As an
independent variable FEV1 has been included as FEV1/
height2,15 and as FEV1/height
3.16 As an outcome variable
examples can be found of FEV1 adjusted for height directly
in a multiple regression analysis,17 and of FEV1/height
2,18 as
well as of FEV1 expressed as percentage of predicted value
for height, age and gender.19 Analyses with FEV1 expressed
as FEV1/height
2 or FEV1/height
3 normally include age as an
independent variable, and also gender if results are
combined for men and women. Similar variation exists in
analyses of FVC.
Lack of uniformity of expression hampers comparisons of
results between studies, and hence of the progression of
research. Agreement on the method of adjustment of FEV1
and FVC for height would be beneficial to all analysing lung
function data or using lung function to define patient
categories.
A criterion that can be used to choose between the several
options is that of best prediction of total mortality. Low lung
function is associated with all cause mortality in both men and
women.2,8,9,15,20 Not only is the association present after
adjusting for age, smoking, body mass index (BMI), and other
risk factors,2,8,9,20 it has been reported to be similar in
magnitude for current, former and never smokers.2,9 Hole et
al.8 found FEV1 to be second in importance to cigarette
smoking as a predictor of all cause mortality.
It is not possible to deduce from the literature which of
the methods of FEV1 adjusted for height gives the best
prediction of total mortality, or whether percentage, rather
than absolute, difference from predicted gives the most
information, as is often assumed. This paper sets out to
answer this question, using a large long-term cohort study
carried out in and around Reykjavik, Iceland.21
Materials and methods
Study participants
The Reykjavik Study, initiated in 1967 as a prospective study
of cardiovascular disease, has been described in detail
previously.21,22 A population register as of 1st December
1966 was used to identify males born 1907–1934 and females
born 1908–1935 resident in Reykjavik or adjacent commu-
nities, where about half the population of Iceland lived at that
time.21 Men and women were divided into six strata with
similar year of birth distribution, with staggered years of first
invitation to participate, and up to five follow-up visits.
Spirometry
Spirometry was performed with a Vitalograph (Vitalograph
Ltd., Buckingham, UK) at each survey. One machine wasused up until 1974, a second until 1983, and a third
throughout the study. Each machine was regularly calibrated
with a 1 l syringe. Three attempts were recorded for FEV1
and FVC. Smoking status was recorded at each survey.
Participants were divided into never smokers at baseline,
current or ex-smokers of only pipe or cigars, ex-cigarette
smokers and current cigarette smokers; the small number of
women who reported ever smoking only pipe or cigars were
excluded. BMI was calculated as weight in kilograms divided
by the square of height in metres.
Selection of data
The data were reviewed as longitudinal records for outliers,
using a number of criteria. There were a substantial number
of outliers in the lung function data in the years up to 1975,
but few in the later period, so data were restricted to those
collected at or after 1st March 1976. For each participant
data from the first survey at or after 1st March 1976, which
coincided with the first visit for three strata, were used in
the analysis. The sixth stratum, not surveyed until
1991–1996, was omitted. Follow-up for this analysis was
until death, or until 1st January 2002 for survivors at that
date.
Data analysis
Cox proportional hazards regression was used to relate total
mortality to age, BMI, period of survey, baseline smoking
groups, and either FEV1, FEV1/height
2, FEV1/height
3, FEV1%
predicted or FEV1 as difference from predicted value. Three
sets of predicted values were calculated, two using
published equations,23,24 the other internally derived values
using regression of baseline FEV1 on age and height for non-
smoking men and women separately. Survival from time of
lung function measurement was used as the timescale.
When non-linearity in the relation of mortality to lung
function was detected each measure of lung function was
divided into quintile groups so that comparisons could be
made. In each of the analyses for each of the nine measures
of lung function there were the same number of participants
and the same number of fitted parameters, so relative
strength of the relation of lung function to mortality was
directly measured by the likelihood ratio w2 statistic.
Age at baseline was grouped into five categories, o50,
50–o55, 55–o60, 60–o65 and 65 years and over. BMI was
divided into underweight (BMIo20), normal weight (BMI
20–o25), overweight (BMI 25–o30) and obese (BMIX30).
Interactions between smoking and measures of FEV1 were
tested. The same analyses were carried out for FVC. All
analyses were performed for men and women separately.
Selected height-adjusted predictors of mortality were
divided into equal width groups. The effect of adjusting for
age, smoking and BMI was assessed by comparing hazard
ratios from Cox proportional hazards regression. As all
participants were followed up until death or for longer than
10 years, predicted 10 year survival rates were estimated
using logistic regression.
The National Bioethics Committee and the Data Protec-
tion Authority of Iceland approved the study protocol. All
participants provided informed consent.
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Sample characteristics
Overall response rates at first visit in the three periods of
survey were 71.5%, 70.9% and 64.4% for men, and 68.7%,
71.0% and 65.6% for women. Response was higher among
married than unmarried men and women, and in younger
than in older people. In 1976 or later 13,606 residents took
part in a survey, 5544 men and 8062 women. By 1st January
2002, 2298 (41.5%) men and 2314 (28.7%) women had died.
Almost all who attended had baseline data on height and
weight and acceptable lung function, 13,489 in total.
Mean height and lung function were related to age, each
being greatest in the younger participants (Table 1). About
half the sample was overweight or obese at baseline, 47.2%
men overweight and 11.3% obese, 34.9% women overweight,
12.2% obese, while 3.4% of men and 6.3% of women were
underweight.
At baseline there were 1260 men and 3581 women who
had never smoked, 625 men who had ever smoked only pipe
or cigars, 2284 men and 1577 women who were ex-cigarette
smokers, and 1308 male and 2768 female current smokers.Analysis of FEV1
Hazard ratios for lung function did not differ significantly
between the four smoking groups in men, for any measure of
lung function (P40.5), or between the three smoking groups
included in women (P40.1). There was evidence for non-
linearity in the association of mortality with most measures
of lung function. Results, adjusted for smoking group, are
therefore shown in Table 2 by quintile group of FEV1
measure. Results are shown for FEV1% predicted or
difference from predicted using the European Coal and
Steel Community (ECSC) equations,23 as both the internally
derived predicted values and those derived from US
reference equations24 were less predictive of total mortal-
ity. FEV1/height
2 was the best predictor of mortality after
FEV1 without height adjustment in men, and the best
predictor of mortality in women. FEV1/height
3 was a better
predictor than FEV1% predicted or difference from pre-Table 1 Mean height, forced expiratory volume in 1 s (FEV1) and
Age group (years) o50 50–o55
Men
Number in sample 922 1280
Mean (SD) height (m) 1.80 (0.06) 1.78 (0.06)
Mean (SD) FEV1 (L) 3.84 (0.66) 3.48 (0.64)
Mean (SD) FVC (L) 4.81 (0.75) 4.38 (0.73)
Mean (SD) BMI (kgm2) 25.7 (3.4) 26.0 (3.6)
Women
Number in sample 1217 1614
Mean (SD) height (m) 1.65 (0.05) 1.64 (0.05)
Mean (SD) FEV1 (L) 2.74 (0.54) 2.50 (0.52)
Mean (SD) FVC (L) 3.49 (0.59) 3.20 (0.59)
Mean (SD) BMI (kgm2) 24.7 (3.9) 25.1 (3.8)dicted. The hazard ratio for current cigarette smokers
compared to never smokers was from 1.84 to 1.88 in men,
depending on the adjustment for FEV1, with that for ex-
cigarette smokers 1.25–1.27, and for pipe or cigar smoking
1.21–1.22. In women, current cigarette smokers had a
hazard ratio of 1.69–1.71 and ex-cigarette smokers
1.12–1.15.Analysis of FVC
FVC was less predictive than FEV1 (Table 3). FVC/height
2 was
the best associated with mortality of the height adjusted
measures for men and women, but for men difference from
predictive value was better associated than FVC % predicted
or FVC/height3. Results using internally derived predicted
values or the US equations again gave less good prediction
than using the ECSC equations.FEV1/height
2 versus FEV1/height
3
Both FEV1/height
2 and FEV1/height
3 differed significantly in
mean value between men and women (Po0.0001), but
there was relatively less difference in FEV1/height
3 (men:
mean 0.580, SD 0.126 Lm3; women: mean 0.525, SD 0.125)
than in FEV1/height
2 (men: mean 1.024, SD 0.225 Lm2;
women: mean 0.855, SD 0.206).Predictive power of FEV1/height
2 and FEV1/height
3
The hazard ratios associated with FEV1/height
2 divided into
equally spaced groups are shown in Table 4, with adjustment
for period survey, and with adjustment for other predictive
factors added cumulatively. Although the predictive power
of low lung function was reduced by adding in age group,
and further reduced by information on smoking, there was
very little confounding by BMI. Table 5 shows the estimated
10-year mortality rates for men and women by grouped
values of FEV1/height
3, age and smoking. Although predic-
tion is slightly better using FEV1/height
2 the table is simpler
in form using FEV1/height
3 due to the closer similarity of
range of values for men and women.forced vital capacity (FVC) in men and women by age group.
55–o60 60–o65 X65
1498 788 1019
1.77 (0.06) 1.75 (0.06) 1.73 (0.06)
3.19 (0.66) 2.92 (0.66) 2.55 (0.64)
4.05 (0.76) 3.77 (0.71) 3.39 (0.75)
26.0 (3.6) 25.9 (3.5) 25.7 (3.6)
2301 1336 1514
1.63 (0.05) 1.62 (0.05) 1.60 (0.05)
2.31 (0.50) 2.06 (0.50) 1.82 (0.50)
2.98 (0.57) 2.71 (0.58) 2.39 (0.59)
25.4 (4.3) 25.6 (4.4) 25.8 (4.7)
A
R
TIC
LE
IN
PR
ES
S
Table 2 Hazard ratio relative to lowest quintile group for total mortality in all men and women, for each measure of baseline FEV1, adjusted for smoking group, age group,
period of survey, and BMI category.
Baseline lung function
measure
Quintile
group
Men (n ¼ 5507) Women (n ¼ 7926)
Hazard ratio relative to
lowest quintile group
95% confidence
interval
w2 statistic
(4 degrees of
freedom)
Hazard ratio relative
to lowest quintile
group
95% confidence
interval
w2 statistic
(4 degrees of
freedom)
FEV1 (L) II 0.67 0.59–0.75 110.66 0.61 0.55–0.68 211.59
III 0.62 0.55–0.70 0.48 0.42–0.54
IV 0.55 0.48–0.63 0.46 0.40–0.53
V 0.50 0.42–0.58 0.39 0.33–0.46
FEV1/height
2 (Lm2) II 0.75 0.67–0.84 89.75 0.63 0.56–0.70 226.02
III 0.66 0.58–0.75 0.48 0.42–0.54
IV 0.58 0.51–0.67 0.44 0.39–0.51
V 0.52 0.44–0.61 0.40 0.34–0.47
FEV1/height
3 (Lm3) II 0.80 0.68–0.85 78.73 0.64 0.57–0.71 212.20
III 0.66 0.59–0.75 0.50 0.44–0.57
IV 0.63 0.55–0.73 0.46 0.40–0.52
V 0.54 0.47–0.63 0.41 0.36–0.48
FEV1%predicted (ECSC) II 0.74 0.65–0.83 75.69 0.61 0.55–0.69 182.45
III 0.70 0.62–0.79 0.56 0.49–0.63
IV 0.66 0.58–0.75 0.52 0.45–0.59
V 0.57 0.50–0.65 0.45 0.39–0.51
Difference in FEV1 from
predicted (ECSC) (L)
II 0.76 0.67–0.85 65.33 0.63 0.56–0.71 173.91
III 0.72 0.64–0.82 0.56 0.50–0.64
IV 0.67 0.59–0.76 0.51 0.45–0.59
V 0.59 0.52–0.68 0.45 0.39–0.51
ECSC—European Coal and Steel Community prediction equations.23
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Table 3 Hazard ratio relative to lowest quintile group for total mortality in all men and women for each measure of baseline FVC, adjusted for smoking group, age group,
period of survey, and BMI category.
Baseline lung function
measure
Quintile
group
Men (n ¼ 5506) Women (n ¼ 7924)
Hazard ratio relative to
lowest quintile group
95% confidence
interval
w2 statistic
(4 degrees of
freedom)
Hazard ratio relative
to lowest quintile
group
95% confidence
interval
w2 statistic
(4 degrees of
freedom)
FVC (L) II 0.70 0.62–0.79 87.46 0.64 0.58–0.72 192.41
III 0.63 0.55–0.71 0.52 0.46–0.59
IV 0.60 0.52–0.69 0.46 0.40–0.53
V 0.52 0.44–0.61 0.38 0.33–0.45
FVC/height2 (Lm2) II 0.73 0.65–0.82 66.98 0.64 0.57–0.72 220.35
III 0.70 0.61–0.79 0.51 0.45–0.57
IV 0.67 0.59–0.77 0.42 0.36–0.48
V 0.54 0.46–0.64 0.39 0.33–0.46
FVC/height3 (Lm3) II 0.76 0.68–0.86 50.34 0.65 0.58–0.73 209.55
III 0.73 0.64–0.83 0.50 0.44–0.57
IV 0.70 0.61–0.80 0.46 0.40–0.52
V 0.61 0.52–0.71 0.40 0.34–0.47
FVC %predicted (ECSC) II 0.83 0.74–0.94 48.68 0.64 0.57–0.73 186.03
III 0.70 0.61–0.79 0.57 0.50–0.65
IV 0.74 0.65–0.84 0.47 0.41–0.54
V 0.65 0.56–0.74 0.45 0.40–0.52
Difference in FVC from
predicted (ECSC) (L)
II 0.79 0.69–0.89 52.55 0.62 0.55–0.70 197.51
III 0.69 0.60–0.78 0.55 0.50–0.64
IV 0.72 0.63–0.82 0.47 0.40–0.52
V 0.62 0.54–0.72 0.45 0.38–0.50
ECSC—European Coal and Steel Community prediction equations.23
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Table 4 Hazard ratios for total mortality in all men and women for equal spaced groups of FEV1/height
2 and smoking groups.
Risk factor Adjustment Men Women
Hazard Ratio 95% confidence
interval
Hazard Ratio 95% confidence
interval
FEV1/height
2
1.2–o1.6 (Reference group) 1.0 1.00
0.8–o1.2 Period of survey 2.02 1.78–2.29 2.12 1.52–2.96
0.4–o0.8 4.74 4.09–5.49 5.76 4.13–8.04
0–o0.4 9.95 7.35–13.47 14.84 10.24–21.50
0.8–o1.2 Period of survey—age groups 1.37 1.20–1.56 1.34 0.96–1.88
0.4–o0.8 2.22 1.90–2.60 2.51 1.79–3.54
0–o0.4 4.02 2.95–5.48 5.85 4.01–8.55
0.8–o1.2 Period of survey—age
groups—smoking
1.27 1.11–1.45 1.25 0.89–1.75
0.4–o0.8 1.86 1.59–2.19 2.12 1.51–2.99
0–o0.4 3.43 2.51–4.68 4.78 3.27–7.00
0.8–o1.2 Period of survey—age
groups—smoking—BMI groups
1.27 1.11–1.45 1.23 0.87–1.72
0.4–o0.8 1.86 1.59–2.19 2.06 1.46–2.90
0–o0.4 3.43 2.50–4.70 4.59 3.13–6.72
Pipe or cigar smoking only—compared
to never smokers
Period of survey—age—lung function
and BMI groups
1.22 1.04–1.43
Ex cigarette smokers compared to
never smokers
1.27 1.13–1.42 1.13 1.01–1.27
Current cigarette smokers compared
to never smokers
1.88 1.66–2.13 1.74 1.58–1.91
Four groups in men, three in women.
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The objective of this study was primarily to recommend a
method by which the clinical and research communities
might reach agreement on the method of expression of lung
function. We suggest that the measure of adult height-
adjusted lung function that has the strongest association
with total mortality should be chosen. These analyses show
that either index, FEV1/height
2 or FEV1/height
3, is a better
predictor of total mortality than FEV1% predicted or
difference from predicted. Two sets of published predicted
values of lung function for age and height were used, those
in common use in Europe23 which underestimated lung
function in Iceland, and those used in the US24 which
overestimated. The former gave better prediction of
mortality than the latter. Internally derived predicted
values calculated using baseline lung function, age and
height for non-smoking men and women, led to poorer
performance of FEV1% predicted and difference from
predicted, and for FVC, compared to those from the ECSC
equations.23 This is not as surprising as it might first seem.
There is no reason why ideal lung function should necessarily
be quantified by an index independent of height, which is
what internally derived % predicted, or more properly
difference from predicted, provides. As our results show,
the best prediction of total mortality in men is by FEV1
unadjusted for height.
FEV1/height
2 was a better predictor than FEV1/height
3 in
non-smoking men (not shown) and in all men and in all
women with adjustment for smoking, and only slightly
inferior to FEV1/height
3 in non-smoking women (not shown).
FEV1/height
3 has the advantage of a closer range of values in
men and women, and therefore may be more convenient in
practise. Although overall mortality is lower in women, the
gradient of mortality with decreasing lung function was
greater in women, so neither measure is independent of sex.
In non-smokers FVC/height2 was a better predictor than
FVC/height3 in men, with little difference in women. In all
participants, adjusted for smoking, FVC/height2 out-per-
formed all measures in women, and all but unadjusted FVC
in men (Table 3). Clearly the chosen measure should follow
the same form for FEV1 and FVC. While the closer
comparability of FEV1/height
3 than FEV1/height
2 in men
and women is an argument for the former, the prediction
results favor FVC/height2.
The statistical properties of the measures of lung function
were comparable in these data; each was slightly negatively
skewed and variation was not strongly dependant on mean
value. In theory FEV1% predicted and difference from
predicted value can be expected to show differences in
distribution. If variation in FEV1 is independent of mean
value, as assumed by most prediction equations,6 that of
FEV1% predicted can be expected to be heteroscedasctic.
However, from our results neither FEV1% predicted or
difference from predicted value seems to be the measure
best associated with survival from time of lung function
measurement, and there are no strong statistical reasons for
choosing one measure over another.
There is a major advantage in adopting FEV1/height
2 or
FEV1/height
3 in preference to FEV1% predicted, in that a
choice of reference equations is not required, at least not
for all purposes. In an epidemiological study it is likely to be
ARTICLE IN PRESS
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influence on lung function, so any advantage of an age and
sex-adjusted measure of lung function, such as FEV1%
predicted, is lost. FEV1% predicted has similar mean value
in men and women, but may not have equal variation,23 so
should not be analysed in its raw state when data for men
and women are combined. For clinical use reference values
of FEV1/height
2 or FEV1/height
3, whichever is chosen, will
be required, for men and women separately.
The hazard ratio associated with the lowest group of FEV1
compared to the highest was greater than that for smoking,
and there was no statistically significant interaction be-
tween lung function and smoking groups on mortality. It
seems unlikely that the effect of low lung function would be
explained either by physical fitness or socio-economic
factors,25 although associations with social class and
deprivation have been reported after adjustment for a
number of risk factors including FEV1.
11
There was a strong relation between FEV1 and mortality,
in non-smokers as well as in the total sample adjusted for
smoking (not shown). Several survival analyses for total
mortality in relation to FEV1 have adjusted for smok-
ing,8,12,15,20 and usually reported the associated hazard
ratio, but have not stratified or tested the interaction of
smoking and lung function. Lange et al.13 reported an
association of lower FEV1 with increased mortality in never
smokers, but Stavem et al.14 reported no relation in never
smokers, and Knuiman et al.9 found a relation in never-
smoking women but not in men. Each of these studies had
fewer participants than the Reykjavik study, and did not
report whether the interaction term was statistically
significant.
Although the Iceland cohort has follow-up for over 35
years the early lung function data were omitted due to
quality control concerns. Table 5 is a guide to the predictive
power of lung function for 10-year mortality. We hope that
other researchers, especially those with measurements at
younger ages and with longer follow-up, will be prompted to
analyse lung function and mortality data to further the
debate and allow a final recommendation for use of FEV1/
height2 or FEV1/height
3.
In the 1960s and 1970s, there was inconsistency in the
measures of weight for height in use.26 This was resolved in
the 1980s for adults, when BMI was finally adopted with
generally agreed cut-off points for overweight and obesity,
largely based on the relation of BMI to mortality, and in the
1990s for children when cut-off points for BMI equivalent to
those in adults were proposed.27 Although some debate over
cut-off points continues, there is now little disagreement
with the use of BMI in adults or children. There is a much
greater case for choosing the measure of lung function based
on its relation to total mortality than in using mortality to
select a measure of weight-for-height. The research and
clinical communities will benefit if agreement can be
reached over the appropriate measures of height-adjusted
lung function.Acknowledgements
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